403
Sorry!!
Error! We're sorry, but the page you were
looking for doesn't exist.
Theratechnologies Inc.
(MENAFN- Baystreet) 11:19 AM EST - Theratechnologies Inc. : Today presented data from a real-world, observational, registry study demonstrating the efficacy and safety of ibalizumab in reducing HIV RNA to undetectable levels in heavily treatment-experienced (HTE) patients with multidrug resistant HIV. Theratechnologies Inc.
shares T are trading up $0.03 at $2.21.
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.
Comments
No comment